Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Liabilities and Shareholders Equity (2016 - 2025)

Aptevo Therapeutics' Liabilities and Shareholders Equity history spans 11 years, with the latest figure at $27.0 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 78.24% year-over-year to $27.0 million; the TTM value through Sep 2025 reached $66.6 million, down 8.25%, while the annual FY2024 figure was $15.6 million, 37.24% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $27.0 million at Aptevo Therapeutics, up from $15.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $71.5 million in Q2 2021 and bottomed at $8.3 million in Q1 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $28.9 million (2023), against an average of $33.7 million.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 286.16% in 2021 before it crashed 52.68% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $56.6 million in 2021, then plummeted by 39.55% to $34.2 million in 2022, then dropped by 27.39% to $24.8 million in 2023, then tumbled by 37.24% to $15.6 million in 2024, then skyrocketed by 73.15% to $27.0 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Liabilities and Shareholders Equity are $27.0 million (Q3 2025), $15.6 million (Q2 2025), and $8.3 million (Q1 2025).